舒泰神(300204) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥94,983,395.63, representing a 46.09% increase compared to ¥65,017,235.12 in the same period last year[3] - The net loss attributable to shareholders decreased to ¥3,769,395.63, a 92.26% improvement from a loss of ¥48,725,047.50 in the previous year[3] - The net cash flow from operating activities improved to -¥17,031,862.23, a 65.03% reduction in loss compared to -¥48,703,447.32 last year[3] - Basic and diluted earnings per share improved to -¥0.01, a 90.00% increase from -¥0.10 in the same period last year[3] - The company reported a significant increase in operating income of ¥29,966,160.51, or 46.09%, primarily due to increased product sales[9] - Total operating revenue for Q1 2024 was CNY 94,983,395.63, an increase of 46% compared to CNY 65,017,235.12 in the same period last year[27] - Comprehensive income for the period was CNY 8,418,612.81, a significant recovery from a loss of CNY 78,828,739.97 in the same quarter last year[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,311,959,988.12, a decrease of 1.52% from ¥1,332,220,277.68 at the end of the previous year[4] - The company reported a total current assets of CNY 222,129,955.69 as of March 31, 2024, down from CNY 238,887,783.46 at the beginning of the year[25] - The company's total assets amounted to CNY 1,311,959,988.12 as of March 31, 2024, compared to CNY 1,332,220,277.68 at the beginning of the year[25] - Total liabilities decreased to CNY 282,873,497.03 from CNY 311,552,399.39, a decrease of about 9.2%[28] - Deferred income tax liabilities decreased to CNY 56,691,439.48 from CNY 74,142,262.33, a reduction of approximately 23.5%[28] - The company reported a total non-current assets of CNY 1,089,830,032.43 as of March 31, 2024, compared to CNY 1,093,332,494.22 at the beginning of the year[25] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,825[13] - The largest shareholder, Yizhao (Beijing) Pharmaceutical Technology Co., Ltd., holds 36.11% of shares, totaling 172,532,363 shares[13] - The top ten shareholders include major entities such as Xiangtang Group Limited, holding 8.68% of shares[13] - The total number of shares held by the top ten unrestricted shareholders is 172,532,363 shares[13] - The company reported a total of 6,133,371 restricted shares held by executives, with a release date set for February 11, 2025[15] - The company has not disclosed any other significant shareholder relationships or actions beyond those mentioned[13] Research and Development - Research and development expenses decreased by ¥30,193,605.99, a reduction of 49.59%, attributed to lower R&D spending in the current period[9] - R&D expenses significantly decreased to CNY 30,691,001.31 from CNY 60,884,607.30, a reduction of about 49.6%[27] - The company received approval for clinical trials of STSA-1001 injection for cancer pain treatment on January 3, 2024[14] - BDB-001 injection showed good safety and tolerability in patients with hidradenitis suppurativa, with a positive correlation between drug concentration and dosage[16] - The company received approval for clinical trial applications for STSP-0902 injection for the treatment of oligospermia on April 12, 2024[18] - The company also received approval for clinical trial applications for STSP-0902 eye drops for the treatment of neurotrophic keratitis on April 12, 2024[18] Operational Changes - The company experienced a 576.63% increase in accounts receivable, rising by ¥17,018,028.41, primarily due to the transfer of certain receivables at the end of the previous year[9] - The company reported a significant increase in other operating expenses, which rose by ¥559,285.07, or 1627.40%, mainly due to donations made during the period[10] - The company decided to terminate clinical trials for several projects related to COVID-19 due to the current pandemic situation[17] - The company announced the termination of certain clinical trial projects on March 26, 2024[20] - The company is focusing resources on advancing key research projects to milestone stages[20] - The company plans to absorb and merge its wholly-owned subsidiary Zhejiang Shutai on March 26, 2024[20] Cash Flow - The net cash flow from investment activities was -4,955,311.49, compared to 8,184,269.95 in the previous period[32] - The total cash inflow from financing activities was 688,720.00, while the cash outflow was 13,348,248.78, resulting in a net cash flow of -254,777.84[32] - The net increase in cash and cash equivalents was -22,198,903.36, down from -52,982,566.14 in the previous period[32] - The ending balance of cash and cash equivalents was 62,981,635.34, compared to 212,005,194.21 at the end of the previous period[32] Audit and Reporting - The company did not undergo an audit for the first quarter report[33] - The report was released by the board of directors on April 25, 2024[34]